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Background: Total hip replacement provides pain relief and improves physical function and quality of life in patients
with end-stage hip osteoarthritis. The incidence of hip replacement operations is expected to increase due to the
growing elderly population. Overall, the posterior approach and lateral approach are the two most commonly used
approaches for hip replacement operations. The posterior approach is associated with an increased risk of revision due
to dislocations, and some studies have shown that the lateral approach is associated with reduced patient-reported
outcomes, including physical function and pain; however, this has not been investigated in a randomised controlled
trial with a twelve-month follow-up. We hypothesized that the lateral approach has an inferior outcome in
patient-reported outcome compared with the posterior approach after one year.
Methods/Design: The trial is a prospective, double blinded, parallel-group controlled trial with balanced
randomisation [1: 1]. Patients with hip osteoarthritis scheduled for hip replacement surgery, aged 45–70 years,
will be consecutively recruited and randomised into two groups. Group A will receive hip replacement using the
posterior approach, and Group B will receive hip replacement using the lateral approach. The primary end-point
for assessing the outcome of the two interventions will be twelve months after surgery. Follow-up will also be
performed after three and six months. The primary outcome is Hip Disability and Osteoarthritis Outcome Score,
subscale of “Physical function Short form” (HOOS-PS) Secondary outcome measures include two other subscales
of HOOS (“Pain” and “Hip related Quality of Life”), physical activity level (UCLA activity score), limping (HHS) and
general health status (EQ-5D-3L). Explorative outcomes include physical function test, 3D-gait-analysis and
muscle strength.
Discussion: To our knowledge, this is the first randomised controlled trial comparing the posterior approach with the
lateral approach with patient reported outcome as the primary outcome and with a twelve-month follow-up.
Trial registration: Clinicaltrial.gov: NCT01616667.
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Hip osteoarthritis (OA) is a common and progressive
joint disease causing pain, reduced physical function and
reduced quality of life. Total hip replacement (THR)
provides pain reduction and improves physical function
and quality of life in most patients with end-stage hip
OA [1,2]. In the US, 427,000 hip replacements are per-
formed each year [3]. In Denmark (DK), approximately
10,000 primary and 1,600 revision operations are per-
formed each year, and the incidence is expected to increase
due to the growing elderly population [4]. In DK, the
majority (95%) of the procedures are performed using the
posterior approach (PA). In contrast, the lateral approach
(LA) is more widely used internationally [5,6], and overall
PA and LA are the two most commonly used approaches
for THR [6,7].
PA is associated with an increased dislocation rate and
revision rate due to dislocations compared with LA
[5,8,9]. This may be due to dysfunction of the posterior
soft tissue structures after PA surgery, although these
are repaired in some cases [10]. Regarding patient-
reported outcome measures (PROM), some studies
comparing PA with LA have shown that LA is associated
with reduced outcome, including physical function and
pain [6,11,12]. Furthermore pronounced limping [13,14]
and reduced hip abductor muscle strength may be as-
sociated with LA [15,16]. This might be explained by
the surgical damage on the lateral structures around
the hip joint [6,7,17]; however, these outcomes have
never been evaluated in randomised controlled trials
(RCT) with more than three month follow-up [18]. A
Cochrane review from 2004 did not include PROMs as
outcome measures due to lack of studies evaluating the
patient perspective [7]. Thus, the extent to which the
choice of approach affects the outcome from a patient’s
perspective is largely unknown [7].
To investigate the influence of surgical approach on
patient-reported outcome after THR and with the per-
spective of reducing risk of revision, an RCT is needed
that investigates potential differences between PA and LA.
This trial will provide new evidence regarding the patient’s
perspective, including a twelve-month follow-up, upon
which the choice of approach can be made.
Aim
The primary aim of this trial is to evaluate the postoperative
effect of surgical approach after THR on patient-reported
physical function. The secondary aim is to evaluate the ef-
fects on patient-reported pain, physical activity and quality
of life; further, to evaluate objective measures of physical
function, gait and hip muscle strength. We hypothesize
that patient-reported and objective outcome measures
within the first year will improve more in patients receiving
the PA compared with LA.Methods/Design
Study design
A prospective, double-blinded, parallel-group controlled
trial with balanced randomisation [1:1], in accordance
with CONSORT guidelines [19]. The trial is registered at
ClinicalTrial.gov (NCT 01616667).
Participants and recruitment procedure
Patients will be referred from general medical practitioners
to the outpatient clinic at the Department of Orthopaedic
Surgery and Traumatology, Odense University Hospital
(OUH). The clinic has two locations; one in the city of
Odense at OUH, and one in the city of Svendborg at
Svendborg Hospital, Denmark. Patients, aged 45–70 years,
with indication for cementless THR based on symptoms,
clinical and radiological findings, will be screened according
to the in- and exclusion-criteria, listed in Table 1. Eligible
patients will be given oral and written information about
the trial. Subsequently, an appointment with the principal
investigator (SR) is made, and the patients are screened
again according to the exclusion criteria. The 30 second
chair-stand-test (30s-CST) and Orientation-Memory-
Concentration Test (OMC test) will be performed to
ensure that no patients have severe medical conditions
compromising their physical performance or any men-
tally disturbances influencing their ability to cooperate
during physical testing or complete questionnaires.
The patients will be given an introduction to completing a
patient diary and filling in the questionnaires. Upon signing
the informed consent, the baseline measures are performed.
Finally, patients will be randomised and scheduled for op-
eration by a secretary not involved in the trial.
Setting
Baseline measurement, randomisation, THR operation
and follow-up will take place at OUH, Odense. The
surgical intervention will be performed by a surgeon
from one of two teams of experienced orthopaedic
specialists. One team consists of three surgeons, all
with special training in LA, and they will perform all LA
operations. The other team consists of three surgeons, all
with special training in PA, and they will perform all PA
operations. Selection of component sizes will be based on
preoperative templating performed in TraumeCad®, using
standardised pelvic and anterior-posterior hip x-rays and
finally adjustments on findings during surgery, if neces-
sary. All patients will receive the same type of cementless
components (Bi-metric stem® and Exceed ABT Ringloc-x
Shell™). Standardised information about surgical proced-
ure, complications, care during hospital stay and rehabili-
tation will be given. All patients will receive a standardised
medical regime, including pre- and post- operative anti-
biotic within the first 24 hours, and 7 days of thrombo-
prophylaxis. Local analgesia infiltration (150 ml Naropin®
Table 1 Criteria for participants in the trial
Inclusion criteria Exclusion criteria
Age: 45–70 years, both years included More joints (hip, knee or ankle) with expected joint replacement within a year
Patients scheduled for primary cementless total hip replacement Prior joint replacement on any joints (hip, knee or ankle), or any joint related
surgery on lower limbs, still providing symptoms
Endstage primary hip OA or secondary OA due to mild hip
dysplasia (CE-angle >20 degrees)
BMI >35
Any physical disability preventing patients from walking 20 meters without aid
Any neurological disease (ex. cerebral thrombosis, Parkinson) compromising the
walking ability
Any severe medical condition compromising the physical function (ex. Chronic
heart failure, chronic obstructive pulmonary disease) Evaluated by 30s-CST-test
Severe dementia (OMC < 18)
Inability to read and understand Danish writing and oral instructions
Does not wish to participate
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(1 mg/ml)) will be given before closure of the wound.
Postoperatively, the patients will be given a standardised
self-administrated analgesic regime that includes paraceta-
mol 1000 mg four times daily and 10 mg morphine tablets
when needed. If any additional or alternative analgesic
treatment is necessary, this will be recorded in the patient
dairy. The patients will be instructed on how to take
the morphine tablets by the principal investigator (SR)
prior to the operation and by ward nurses during the
in-hospital stay. They are instructed to take a tablet if
they have pain >3 on the numeric ranking scale (NRS)
for pain (see Explorative Outcomes), when at rest in
bed/chair, or when they are in pain ≥5 on the NRS
scale during activity. The patients will each day receive
a random number (six to eight) of morphine tablets in
a small plastic bag. If the patient needs more tablets,
than are in the bag, the ward nurses will provide the
patient with additional tablets, and this will be regis-
tered. After 24 hours, the bags will be recollected and
remaining tablets will be counted and registered. The
postoperative mobilisation will be performed by a physio-
therapist. Standardised rehabilitation protocol (no matter
which type of intervention) will be applied, including
weight bearing as tolerated and no movement restrictions.
The patients will be mobilised to standing position on the
day of operation. The following days, the patients will be
trained in transfer situations needed in daily activities (in
and out of bed, up and down from chair) and walking with
two canes and on stairs. Following surgery the patients are
instructed in a home based rehabilitation program with 11
exercises. The 11 exercises’ primary focus is strengthening
of the hip muscles by use of elastic bands. The patients
are instructed to conduct this program three times a day,
repeating each exercise 10 times for each leg. When they
can perform 30 repetitions of each exercise on the oper-
ated leg, they should increase the intensity by using anelastic band around the ankles during exercise. They are
instructed to continue the exercise program for at least
three months. If the physiotherapist finds it necessary, the
patient will be referred to additional training provided by
a local physiotherapist. The latter will be recorded.
Intervention
During the operation, all patients will be positioned in
lateral decubitus position.
Posterior approach
PA is performed through an incision over the posterior
part of greater trochanter through the fascia, followed by
blunt dissection of gluteus maximus. Then detachment
of the external rotators and incision of the posterior part
of the hip capsule [20]. The hip is dislocated by internal
rotation and flexion. During closure, capsular repair and
re-insertion of the external rotators are performed.
Lateral approach
LA is performed through a midline incision over the
greater trochanter and involves detachment of the anterior
one-third of the gluteus medius insertion and gluteus
minimus insertion on the tip of greater trochanter. Ex-
cision of the hip capsule is performed on the anterior
side of the joint, from the basis of collum femoris to
the acetabular rim. The hip is dislocated by external
rotation, adduction and flexion. During closure of the
wound, re-insertion of the detached part of muscle glu-
teus medius and muscle gluteus minimus is performed.
There is no capsular repair [14]. All wounds will be
closed with nylon to avoid visible suture clips on the
postoperative radiographs.
Outcome measures
One primary outcome has been chosen to avoid problems
with interpretations associated with multiplicity of analysis
Rosenlund et al. BMC Musculoskeletal Disorders 2014, 15:354 Page 4 of 13
http://www.biomedcentral.com/1471-2474/15/354[19]. The primary outcome will be supported by several
other patient reported secondary and tertiary outcome




Hip Disability and Osteoarthritis Outcome Score (HOOS
2.0), subscale “Physical Function Short form (HOOS-PS)”,
will be used as the primary outcome, with primary end-
point after twelve months. The subscale HOOS-PS is an
aggregation and shortening of the two original subscales
of HOOS-ADL and Sport and Recreation. It has been de-
veloped to optimize the measurement of physical function
and at the same time lower the burden of long question-
naires for the patients. The HOOS-PS subscale includes
five items (three from HOOS-ADL and two from HOOS
sport and recreation) that cover a wide range of physical
functions, from low demand to high demand functions
[21] It is a disease-specific patient-reported outcome
measure developed to assess the patients’ opinion about
their hip associated problems [22-24]. The subscale
ranges from 0 point (extreme symptoms) to 100 point
(no symptoms). HOOS-PS has been evaluated regarding
validity and responsiveness in THR patients. HOOS-PS
was found to have high internal consistency and respon-
siveness [24]. HOOS 2.0 has been evaluated regarding
validity and reliability in THR patients. It was found to
have high content validity, construct validity, test-retest
reliability, responsiveness and interpretability [22]. One
study also found good internal consistency and little
floor and ceiling effect [25]. All items of HOOS 2.0 has
been translated into Danish [26].
Secondary outcomes
HOOS 2.0
HOOS subscale for pain, and hip related Quality of life
(QoL) will also be reported.
General health status
EuroQol/EQ-5D [27] is a patient-reported generic gen-
eral health questionnaire. The first part evaluates the
following five dimensions; mobility, self-care, normal
activities, pain/discomfort and anxiety/depression, and
uses a 3-point Likert scale for each dimension. The
second part evaluates the patients’ perception of their
overall health and is scored on a 100-point visual
analogue scale. EQ-5D has been validated in knee OA
patients [28], where the construct validity was found
acceptable. Although EQ-5D is not validated in a THR
population, it can be recommended for evaluating health
related quality of life (HRQoL) with EQ-5D in these pa-
tients [29]. The test-retest reliability has been shown mod-
erate to good in healthy and knee OA patients [28,30].The responsiveness was good in rheumatoid arthritis
populations and in patients with femoral neck fractures
[31,32]. The floor effect is negligible, but a high ceiling
effect has been found in THR patients [33]. EQ-5D is
translated into Danish [34].
Physical activity
The University of California Los Angeles activity score
(UCLA) uses a 10-point Likert scale to evaluate activities,
ranging from inactive to regular participation in impact
sport or heavy labour. UCLA has been validated in pa-
tients undergoing hip or knee joint replacement [35]
with good construct validity, test-retest reliability [35,36],
moderate responsiveness, low ceiling and floor effect [36].
UCLA contributes with important qualitative information
on the patients’ physical activity in correlation with other
clinical outcome measures [35,37]. UCLA is translated
into Danish.
Limping
Harris Hip Score (HHS) is a disease-specific surgeon-
reported questionnaire. It includes four domains: pain,
function (subdivided in ADL and gait), deformity and
joint motion. In this trial, only the question from the
function domain, regarding the amount of limping, is
used. It is scored on a 5-point Likert scale (none, slight,
moderate, severe limp or unable to walk). The question
will be used as a patient-reported outcome to evaluate
the patient’s own experience of limping during gait. The
reliability and validity of HHS is tested in a THR popula-
tion and showed low floor effect but high ceiling effect.
The test-retest and inter-observer reliability was good.
Internal consistency showed high Cornbach α value in
each domain [38]. HHS is translated into Danish.
Explorative outcomes
Physical function test
Prior to each test, the patient will be orally instructed on
how to perform the test. Regarding all maximal physical
function tests, the patient is instructed to perform the
test as fast as possible; however, while still feeling secure.
No oral feedback will be provided during the tests. Assist-
ive devices will be allowed at the follow-up assessments
when needed, but not at baseline, according to the exclu-
sion criteria. However, use of the arms to assist rise from
the chair in 30s-CST is allowed. Both will be recorded.
The 20 meter walk-test
In the 20 meter walk-test (20WT), patients are instructed
to walk 20 meters between two clearly visible lines marked
on the floor. The time for both self-selected normal and
maximal pace is measured, and the number of steps is
counted. The stopwatch is started on the command
“go” after a countdown from “ready, set, go”. The mean
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agreement and excellent test-retest reliability have been
demonstrated in both hip and knee OA patients [39].
“Timed Up and Go” test
The ”Timed Up and Go” test (TUG) measures the time
it takes a person to rise from a chair (seat height 44 cm,
with armrests), walk three meters to a clearly visible line
marked on the floor, turn and walk back to the chair
and sit down again. The stopwatch is started on the
command “go” after a countdown from “ready, set, go”.
The best out of two trials will be used for further analysis
[40]. TUG is used for quantifying functional mobility.
Good construct validity has been reported in knee re-
placement patients [41,42]. Moderate to good test-retest
and inter-rater reliability have been shown in patients with
hip and knee OA [43-45].
The 30 sec-chair-stand-test
The 30 sec-Chair-Stand-test (30s-CST) measures the
number of “stands” completed (seat height 44 cm, with
armrests) within 30 seconds [46]. The best out of two
trials will be used for further analysis. The stopwatch is
started on the command “go” after a countdown from
“ready, set, go”. The test assesses the overall strength of
the lower limb muscles. The 30s-CST has showed valid
as a measure for lower limb muscle strength in active
older adults (60+) [46], and the test showed good intra-
and inter-rater reliability in patients with moderate to
end-stage hip or knee OA [44,45,47].
The 30 sec repeated unilateral knee bending test
The 30 sec repeated unilateral knee bending test
(30s-knee bend) evaluates the ability to execute fast
coupled eccentric-concentric muscle force, with a primary
focus on knee muscle function and a secondary focus on
hip muscle function. The maximum number of knee
bends completed on one leg within 30 seconds will be
recorded. The patient stands aligned with the front of
their foot touching a straight line taped to the floor;
fingertip support for balance is provided by the examiner.
The patient is then asked to bend his/her knee, without
forward trunk lean, until he/she is not able to see the line
at their toes (about 30° of knee flexion) [48]. Three to four
knee bends are performed on each leg to familiarise the
patient with the depth of the flexion. The unaffected leg is
tested first. The stopwatch is started on the command
“go” after a countdown from “ready, set, go”. If the oppos-
ite (raised) leg touches the ground, the trial is stopped,
and the number performed is recorded. One trial on each
leg will be performed. The test was found valid to discrim-
inate between symptomatic and non-symptomatic leg in
meniscectomised patients [48]. Also, it has showed low
floor and ceiling effect in meniscectomised patients [48].It was found reliable with moderate agreement and good
test-retest reliability in patients with hip and knee OA [39].
Trendelenburgs test
The Trendelenburg test will be performed according to
Hardcastle et al. [49]. It indirectly measures the hip ab-
ductor muscles strength, but the validity is disputed [50,51].
Hip ROM
Passive hip range of motion (ROM) will be assessed with
the patient in the supine position, and prone when asses-
sing hip extension. Hip ROM is defined as the range of
movement that an examiner is able to move the hip joint
through its full range with no active participation from the
patient [52]. Hip ROM in flexion/extension, abduction/ad-
duction and internal/external rotation will be measured in
degrees using a standard hand-held goniometer (30 cm)
[53]. The reproducibility has been evaluated in patients
with mild to moderate hip OA and was found poor [53].
Gait analysis and hip muscle strength
Gait deviation index
Gait Deviation Index (GDI) is calculated from kinematic
data collected from 3D-gait-analysis during horizontal
gait. The GDI expresses the degree of gait pathology in
patients compared to healthy subjects, with a mean GDI
of 100 point [54]. 3D gait-analysis is extensively used to
objectively collect both temporospatial, kinematic and
kinetic data. GDI can simplify the complexity of the kine-
matic gait data in THR and other populations [17,55,56].
In unpublished data from our own gait laboratory, we
found good test-retest reliability on GDI. GDI has been
validated in children with cerebral palsy [57].
Hip muscle strength
Isometric maximal voluntary muscle contraction (MVC)
will be used to assess the maximal muscle strength of
the hip abduction, hip flexion and hip extension. MVC
is collected standing, according to the protocol described
by Jensen C. et al. [58]. MVC and rate of force develop-
ment (RFD) will be analysed for both legs. A simple dice
randomisation will be used to determine starting leg and
the sequence of MVC exercise, avoiding a systematic
leg-to-leg learning bias.
For each muscle group, three test contractions will be
performed. The contraction with peak MVC will be
selected for further analysis. The patient will receive
both visual feedback on a monitor and verbal feedback
during each test. MVC has been found reliable in THR
patients [58].
EMG
Surface electromyography (sEMG) is the myoelectric sig-
nals associated with a contraction of a muscle, measured
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use the SENIAM guidelines [59] for skin preparation
and electrodes placement on five selected lower extrem-
ity muscles: muscle gluteus medius, muscle tensor facia
lata, muscle gluteus maximus, muscle rectus femoris,
and muscle semitendinosus. EMG will be collected both
during gait and MVC measurement [55,60]. Peak and
mean EMG signal- (absolute/normalised to MVC) and
integrated EMG during stance phase will be analysed.
The test-retest reliability of sEMG from muscle gluteus
medius normalised to MVC has been evaluated in one
study on 13 young healthy persons, and good reliability
was found. Also, the intra- and inter-individual variabil-
ity of EMG during gait, normalised to MVC in young
healthy persons, has been found good and is therefore
recommended [61,62].
To ensure inter-examiner uniformity, a detailed written
laboratory protocol describing the procedure and the oral
instructions given to the patients during the physical func-
tion tests and MVC assessment has been developed. The
protocol has been rehearsed before evaluating the study
participants.
Patient diary
The patients will complete a diary consisting of four
parts; 1) Pain at rest is measured four times daily using
an 11-point box Numeric Ranking Scale (NRS). The
NRS has been found a reliable, valid and a responsive
tool in geriatric patients [63]. 2) Consumption of pain-
killers. Type, dosage and frequency of pain killers will
be recorded. This is recommended in recent evidence-
based guidelines for management of hip and knee OA
[64] 3) The need for continuous cane use and 4) Com-
pleting the HOOS-pain questionnaire. The diary will be
filled in each day for the first five days and then every
second week until 3 months after surgery.
Digital scanning will be used for questionnaires, and
manual double data entry will be done [65].
Assessments and follow-up period
Assessments point is presented in Table 2. A reminder
will be sent per SMS on all the selected days for
follow-up. The patients will receive the first set of
questionnaires at the outpatient clinic at baseline. The
following three sets, including return envelopes, will
be handed out during the in-hospital stay. Further-
more, a reminder will be send per SMS at three, six
and twelve months. In case of missing return, a new set
and a reminder to complete the questionnaires will be
sent by ordinary post service. All questionnaires will be
completed at the patients’ home. In case of missing
visits for physical function test or assessment in the
gait laboratory, the patient will be contacted by phone,
and a new appointment will be scheduled.Adverse events
A medical record audit will be performed at twelve
months post-surgery. Adverse events regarding peripros-
thetic fracture, nerve palsy, wound infection, deep throm-
bosis or pulmonary embolism, dislocation and revisions
will be collected. Pain will be assessed before and after
all sessions of physical function test, gait-analysis and
MVC measurements. Pain >5 on the NRS is considered
an event that may influence the patients’ effort of max-
imal performance. The assessment of pain will provide
information about the feasibility of the test battery. No
interim analysis or stopping guidelines are planned.
Both interventions are well known and routinely performed
with few severe adverse effects. However; we will register
and report any adverse events to the appropriate health
authorities.
Sample size
Sample size calculation was performed upon the primary
outcome HOOS-PS, using one preoperative and three
follow-up assessments and an estimated correlation
between follow-up measurements of 0.5. We considered a
minimal important difference of 10 points between the
two groups at 12 months follow-up to be of clinical
relevance [66-69] and used a standard deviation of 16.7
and 16.1 postoperatively [24]. We have performed our
sample size calculation using the function “sampsi
method(change)” supported by the Stata 13 software
and described by Frison and Pocook [70]. To achieve a
statistical power of 80% (β = 0.80), it was calculated
that a sample size of n = 29 was needed in each inter-
vention group in order to detect statistical significant
differences at α = 0.05 level. N = 40 was used to ac-
count for possible drop-outs. A secondary sample size
estimation was conducted to estimate the number of
patients needed for analysing the primary explorative
GDI. We had á prior defined that a clinically relevant
improvement in gait function measured in GDI is 7.5
point, which corresponds to half a standard deviation
in the only available randomised clinical trial using
GDI as outcome measure [71]. From data collected in
our own gait laboratory we know that the standard de-
viation in hip OA-patients is 9 point preoperatively
[72]. To achieve a statistical power of 80% (β = 0.80), it
was calculated that a sample size of n = 17 was needed
in each intervention group in order to detect statistical
significant differences at α =0.05 level. Sample size in
each group on n = 20 was used to account for possible
drop-outs.
Randomisation
Balanced 1:1 block randomisation was performed using a
computer-generated list containing a sequence of one let-
ter and one number; “A” referring the patient to posterior
Table 2 Outcomes and assessment points
Assessments point
Primary outcome Data collection instrument (unit) Baseline Post (days) Post (weeks) Post (months)
Function of daily living HOOS-PS Pre 3, 6, 12
Secondary outcomes
Patient reported outcomes
Pain HOOS-pain Pre 3, 6, 12
Quality of life HOOS-QoL Pre 3, 6, 12
Physical activity UCLA Pre 3, 6, 12
General health EQ-5D Pre 3, 6, 12
Limping Harris Hip Score Pre 3, 6, 12
Explorative outcomes
Pain
Pain HOOS-pain Pre 5 2- 10 3
Use of medication (type, quantity) Pre 1- 5 2- 10 3
Short term pain measure NRS Before and after each test (pre- 12 months)
Physical function
20 Meter Walk test (20WT) Stopwatch (s and steps) Pre 3 3 3
Timed Up and Go test (TUG) Stopwatch (s) Pre 3 3 3
Chair Stand - test (30s-CST) (quantity) Pre 3 3 3
Knee Bend test (30s-knee bend) (quantity) Pre 3 3 3
Trendelenburg test (positive/negative) Pre 3
Joint mobility (Hip ROM) Goniometer (degrees) Pre 3
Data from 3D-gait analysis
Total score for kinematic data GDI (points) Pre 3, 12
EMG (frequency and amplitude) Pre 3, 12
Hip Muscle strength MVC (Nm/kg) Pre 3, 12
Rate of forced development 0-200 ms MVC (Nm) Pre 3, 12
Rosenlund et al. BMC Musculoskeletal Disorders 2014, 15:354 Page 7 of 13
http://www.biomedcentral.com/1471-2474/15/354approach, “B” referring the patient to lateral approach.
“1” referring the patient to participate in the gait
analysis and thus contributing with data on GDI, and
“0” referring the patient not to participate in the gait
analysis (Figure 1). Four blocks of 20 patients each
was generated. The sequence was generated by a third
person (JL) not involved in the trial. The letter and num-
ber combination was written on paper, folded and placed
in sealed opaque consecutively numbered envelopes. The
booking secretary will open the envelopes in the given
order, and according to the content the patient will be
scheduled for operation. In the first three blocks there
will be a 66% chance of being allocated to group 1(gait
analysis). This will enable us to verify the sample size
calculation of 2x20 patients for the GDI. A recompilation
will be made, based on ungrouped results of GDI for the
20 first actual gait analyses performed. From this, we will
adjust the final number of patients allocated to gait ana-
lysis accordingly.Blinding
The patients will be blinded to treatment. The patients
are told prior to participation that they will not be
informed about the type of intervention and they are
carefully explained the reasons for this. Also the health
care providers (doctors, nurses and physiotherapists)
are all explained the importance of not talking about
the intervention with the patients, and since the pa-
tients post operatively are treated after the same re-
habilitations protocol, there is no need to discuss
interventions. Blinding to treatment allocation (sur-
geons, ward nurses and, physiotherapists) is not pos-
sible due to the nature of the intervention. However,
the data collectors (except one (DBN) performing gait
analysis) and the principal investigator (SR) analysing
the data will be blinded throughout the trial. We will
use recoded identification numbers when analysing the
data. The recoding will be performed by an independent
person (JL).
Figure 1 Study flow chart.
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Baseline characteristic of study participants, will be
presented with mean and SD, for all relevant outcomes,
according to CONSORT item 15 [19]. The primary
statistical analysis will be performed between the two
groups on mean change in HOOS-PS from baseline to
twelve months follow-up. To evaluate the treatment
effect (mean difference between the groups at three, six
and twelve months), we will employ a random effect
mixed linear model analysis (repeated measures) withpoint estimates [73]. This model includes the inter-
action between treatment and elapsed time, adjusted
for baseline values and assuming that data is missing
completely at random (MCAR) [73]. Model assumptions
will be checked by residual plots. The secondary statistical
analysis will include the same approach as described above
for all the secondary outcomes. We will present the results
with mean and standard deviation for both baseline and
follow-up measurements in the two groups. Furthermore
we will present the adjusted difference in mean between
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effect size using Cohen’s d effect size with indexes for
small, medium and large effect as proposed by Cohen,
1992 will be reported [74]. The intention-to-treat (ITT)
principle will be applied [75]. Subsequent per-protocol
analysis may be needed in case a substantial number of
data is lost during follow-up. All data will be checked for
Gaussian distribution, and parametric statistics will be
used were appropriate. An α-level of 0.05 will be used,
and data presented as means with 95 CI, unless otherwise
stated. Finally, the number needed to treat (NNT) for a
positive effect of treatment (>10 points on HOOS-PS) will
be analysed. All statistical analyses will be blinded and per-
formed using Stata 13 software (StataCorp, Texas, USA).
Ethics
The trial complies with the Declaration of Helsinki. It is
approved by the Danish Data Protection Agency and The
Danish Regional Committee on Biomedical Research
Ethics (Southern Denmark), Project-ID S-20120009. A
written and orally informed consent will be collected
prior to inclusion of all participants.
Discussion
The choice of surgical approach and the influence on
patient-reported outcome, physical function, hip muscle
function and gait are often debated. Especially, the lateral
approach and its impact on the hip abductor muscles are
a concern that may be associated with decreased PROM,
reduced physical function and increased limping. Interest
in reducing the surgical induced muscle damaged is also
emphasised by a study showing that decreased lower limb
muscle strength is associated with deterioration of ADL
functions [76]. Despite this, only few studies have evalu-
ated PROM, physical function and gait between the PA
group and LA group.
PROM
The trial focuses on HOOS-PS as primary outcome after
twelve months, along with a number of secondary out-
comes, in order to evaluate the patients’ perspective on
physical function (HHS-limping), physical activity (UCLA),
pain (HOOS-Pain, EQ-5D) and quality of life (HOOS-QoL,
EQ-5D). All of these are valid measurements and recom-
mended for use in RCTs [77].
To our knowledge, only three studies have investigated
PROM when comparing PA with LA [6,11,18]. Of these
only one study is a randomised controlled trial (RCT)
and did not use PROM as primary outcome. Furthermore,
the three studies do not agree in their conclusions of
which approach is superior in terms of patient reported
physical function and pain. The two non-randomised
cohort studies are demonstrating a small, but signifi-
cant, difference in favour of PA. Contrary, the RCT didnot find any differences in WOMAC, which was evaluated
as a secondary outcome. Also, two studies have compared
the PA with LA using Harris Hip Score (HHS) [12,18];
however, HHS is not entirely patient-reported. The first
study found that LA had a significant inferior outcome on
total HHS after twelve months [12], whereas the other
study found no differences after three months [18].
PROM is recommended by OMERACT (Outcome
Measures in Rheumatologic Clinical Trials) as the core
set of outcome measures in phase III clinical trials in-
vestigating OA treatment, including THR [77]. The
core set outcome includes pain, physical function and
patient global assessment. We have chosen the HOOS-PS
as primary outcome for mainly three reasons. First, phys-
ical function has been defined by OMERACT as one out
of three core set outcomes to evaluate. Physical function
is well reflected in HOOS-PS, which includes 5 items.
Second, we find it relevant to use HOOS-PS as primary
outcome, because it reflects the possible negative influ-
ence of LA due to the surgical damage on the hip ab-
ductor muscles, which could lead to reduced physical
function for these patients. Third, HOOS is in a recent
review recommended for evaluation of THR patients,
because it was found to be the best validated and a reliable
PROM when compared with other commonly used
PROMs (WOMAC, OHS, modified HHS etc.) [22].
Pain is also a core set outcome in the OMERACT
guidelines [77]. Measurements of pain are represented in
both the secondary and the explorative outcomes, by
HOOS-pain, NRS and actual intake of painkillers. Lastly,
a global patient assessment score is the third core set
outcome in the OMERACT guidelines, and it will be
measured by the patients’ perception of their overall
health with the second part of EQ-5D. The use of a spe-
cific question regarding limping from HHS will provide
important information on the gait quality perceived by
the patients and will be further explored using GDI.
Physical function
The surgical induced damaged to the abductor muscles
(muscle gluteus medius and gluteus minimus) may con-
tribute to a decrease of the physical function in the LA
group [6,7,17]. Evaluating the overall early physical func-
tion and the gait performance will contribute with data
that explore this hypothesis further. Also, the physical
function test has shown greater responsiveness during the
early stage after surgery than PROM [42], and it has been
shown that the physical function test may capture a differ-
ent construct of the patients function than patient-reported
physical function. Patient-reported physical function has
shown closer relation to the patients’ perception of pain
[42]. For these reasons, the trial is designed with early
measurement of the patients’ physical function, using a
battery of valid and reliable tests.
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Several trials have found reduced maximal voluntary
muscle strength (MVC) of the hip abductor muscles in
the affected side amongst the THR population [58,78-80].
However, only three non-randomised studies have in-
vestigated MVC of the abductor muscles comparing
PA with LA. Gore et al. [15] found reduced abductor
muscle strength in the LA group, while equal muscle
strength between the two approaches was reported by
Downing et al. [81] and Kiyama et al. [78]. Thus, no
firm conclusion can be draw from the existing literature.
Previously, hip abductor muscle weakness during gait,
evaluated with 3D-gait analysis, has also been reported in
the general THR population [56,60,79,82]. However, only
one study investigating the quality of gait using 3D-gait
analysis has compared LA with PA. This study concluded
that all the LA-patients demonstrated an abnormal gait
pattern, while 30% of the PA-patients had a normal gait
pattern six month after surgery [17]. It was suggested that
the observed abnormal gait pattern in the LA-group
was a compensatory mechanism potential caused by hip
abductor weakness, even though muscle strength was
not assessed [17]. A recent review investigating gait
quality of the THR-population compared with healthy
controls found impairment in several outcomes, includ-
ing gait speed and hip abductor muscle function in the
THR group [83]. Because only few studies until now
have been conducted, Ewen et al. emphasise the import-
ance of investigating the potential differences between sur-
gical approaches in the future [83]. In summary, the
quality and quantity of information extracted from studies
comparing LA with PA performed to date are insufficient
to draw any firm conclusions about physical function,
muscle strength and gait.
Study design
The internal validity of the trial is good, due to same
recruitment procedure, same in/exclusion criteria, same
team taking care of the patients, and the patients experi-
ence the same amount of extra attention regarding the
additional outpatient visits related to testing. The age
limits and the list of exclusion criteria can affect the
external validity and generalizability. However; patients
under the age of 45 are likely to suffer from secondary OA
and in our department all patients over the age of 70 re-
ceive a standard treatment with a cemented prosthetic
concept. Thus, to ensure high internal validity by avoiding
subgroup analysis due to different prosthetic concepts, we
decided only to include patients aged 45–70. The exclu-
sion criteria facilitate investigation of the potential differ-
ences between the two approaches due to the impact on
different soft tissue structures. Thus, the exclusion criteria
enable the investigation of the isolated effect of the
two approaches, without interference of any other healthconditions, which is the primary aim of this trial. We have
chosen the primary end-point at twelve months after
operation, as we expect a stable rehabilitations level at
this point [42]. The intermediate assessments at three
and six months will provide information about potential
differences in the progression of rehabilitation between
the two groups.
We have chosen block randomisation for two reasons:
1) because logistic challenges exist regarding booking of
patients to the surgical theatre combined with a surgeon
from either the LA or PA team. In this way, we ensure
that patients do not wait an unnecessarily long time for
operation, after they are included. 2) The higher chance
(66%) of being allocated to gait analysis in the first three
blocks will enable us to verify the sample size for GDI. If
needed, an adjusted allocation to gait analysis will be
possible in the following block.
We have chosen to randomise the patients to a specific
approach that automatically includes a specific team of
surgeons with specialised skills in that particular approach,
thus avoiding bias due to a learning curve. To avoid the
risk of comparing surgeon skills and/or preference rather
than the surgical procedure, a team of three experienced
surgeons has been included in each group.
The randomisation code will be revealed to the inves-
tigators after the data analysis has been finalised. The
primary outcome and supplementary PROM outcome
will be blinded to the data collectors and data assessor
(SR) throughout the trial, since all questionnaires will
be answered at the patient’s home. The data collectors
are also blinded to intervention when collecting data
regarding the physical test. However, some difficulties
regarding blinding must be mentioned. For practical
reasons, it is not possible to maintain the blinding to
intervention for the data collector (DBN) regarding the
3D gait analysis at three and twelve months’ follow-up,
when placing the EMG electrodes in close relation to
the scar at the hip. However, this will only influence a
subgroup of the trial population and only the collection
of explorative outcomes. Also, we will blind the patients
by not telling them the given intervention, and prior to
intervention we will explain to them why it is important
that they are retained from this information. Nevertheless,
there is a risk that the patient will guess the intervention
from the name of the surgeon.
Conclusion
The present trial will provide evidence for the choice of
approach in the future, with focus on the patients’ per-
spective. The results of the trial will be submitted to
peer-reviewed journals for publication, irrespective of
the outcome, in accordance with the CONSORT guide-
lines for reporting of clinical trials and registration in
ClinicalTrails.gov [84].
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